NCT02481479View on ClinicalTrials.gov

Saxagliptin and Cardiac Structure and Function

PHASE4CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Diabetes Mellitus, Non-Insulin-DependentHeart Failure
Interventions
DRUG

Saxagliptin

Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR

DRUG

Saxagliptin

Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram

DRUG

saxagliptin

Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture

Trial Locations (1)

M5B1W8

St Michael's Hospital, Toronto

All Listed Sponsors
lead

Unity Health Toronto

OTHER

NCT02481479 - Saxagliptin and Cardiac Structure and Function | Biotech Hunter | Biotech Hunter